Publications by authors named "Marta Bellini"

Claim this Profile
D
Design, Synthesis, and Biological Evaluation of the Novel Neutrophil Elastase Inhibitor CHF-6333 for the Inhaled Treatment of Bronchiectasis.
Elisabetta Armani, Andrea Rizzi, Daniela Miglietta, Irene Bassanetti, Francesco Amadei, Marta Bellini

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.
Maria Chiara Finazzi, Silvia Salmoiraghi, Francesca Valsecchi, Chiara Pavoni, Clara Belotti, Marta Bellini

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey.
Bruno Fattizzo, Valentina Carrai, Monica Crugnola, Erminia Baldacci, Marta Bellini

Eur J Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, Alberto Alvarez-Larran, Arianna Ghirardi, Marta Bellini

Ann Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Alessandra Carobbio, Arianna Ghirardi, Marta Bellini

NEJM Evid· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Marta Anna Sobas, Marta Bellini

Am J Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breakthrough infections in MPN-COVID vaccinated patients.
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Bellini

Blood Cancer J· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score.
Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Arianna Masciulli, Greta Carioli, Marta Bellini

Blood Cancer J· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal Newborn Screening for Congenital Cytomegalovirus Infection - From Infant to Maternal Infection: A Prospective Multicenter Study.
Angela Chiereghin, Claudia Pavia, Gabriele Turello, Eva Caterina Borgatti, Federico Baiesi Pillastrini, Marta Bellini

Front Pediatr· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second versus first wave of COVID-19 in patients with MPN.
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Marta Bellini

Leukemia· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
John Mascarenhas, Francesco Passamonti, Kate Burbury, Tarec Christoffer El-Galaly, Aaron Gerds, Marta Bellini

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of recovered MPN patients with COVID-19.
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Marta Bellini

Blood Cancer J· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Arianna Masciulli, Alessandra Carobbio, Marta Bellini

Lancet Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Marta Bellini

Leukemia· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Tiziano Barbui, Valerio De Stefano, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Marta Bellini

Blood Cancer J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics.
Anna Maria Piras, Ylenia Zambito, Maurizio Lugli, Baldassare Ferro, Paolo Roncucci, Marta Bellini

Pharmaceuticals (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Marta Bellini

Blood Adv· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
Valerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, Paola Guglielmelli, Alessandra Iurlo, Marta Bellini

Blood Cancer J· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Elisa Rumi, Emanuela Boveri, Marta Bellini, Daniela Pietra, Virginia V Ferretti

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Chiara Cavalloni, Elisa Rumi, Virginia V Ferretti, Daniela Pietra, Elisa Roncoroni, Marta Bellini

Oncotarget· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neonatal gastrointestinal involvement and congenital cytomegalovirus.
Alessandro Porta, Adriana Avanzini, Marta Bellini, Rosa Maria Crossignani, Stefano Fiocchi

Pediatr Med Chir· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LNK mutations in familial myeloproliferative neoplasms.
Elisa Rumi, Ashot S Harutyunyan, Daniela Pietra, Jelena D Milosevic Feenstra, Chiara Cavalloni, Marta Bellini

Blood· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Elisa Rumi, Jelena D Milosevic, Dominik Selleslag, Ilaria Casetti, Els Lierman, Marta Bellini

Ann Hematol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.
Elisa Rumi, Irene Bertozzi, Ilaria C Casetti, Elisa Roncoroni, Chiara Cavalloni, Marta Bellini

Haematologica· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Elisa Rumi, Daniela Pietra, Cristiana Pascutto, Paola Guglielmelli, Alejandra Martínez-Trillos, Marta Bellini

Blood· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis